A grounded reference on PT-141 (bremelanotide): what it is, how its central melanocortin mechanism differs from PDE5 inhibitors, the RECONNECT Phase 3 evidence behind its FDA approval as Vyleesi, known side effects, and how the research community discusses it, with a research-use-only vendor note.
pt-141, also called bremelanotide, is a synthetic cyclic peptide that acts in the brain to influence sexual desire and arousal. it's a melanocortin receptor agonist, mainly at the MC4 receptor, and it works centrally in the CNS rather than on blood vessels the way viagra-type drugs do. the same molecule is FDA-approved as Vyleesi (1.75 mg subcutaneous) for a specific desire disorder in premenopausal women, and it has an older research history in men's erectile dysfunction.
What PT-141 (Bremelanotide) Actually Is
PT-141 is a synthetic cyclic peptide modeled on alpha-MSH, the body's own melanocyte-stimulating hormone. It is a melanocortin receptor agonist with high affinity for MC4R PMID: 31429064. At therapeutic doses it activates several melanocortin receptor subtypes nonselectively, of which MC4R is the most relevant PMID: 33455598. That receptor targeting is what separates it from every other compound in the sexual-function category.
The mechanism is neurologic, not vascular. MC4R is concentrated in the medial preoptic area (mPOA) of the hypothalamus, a brain region tied to sexual function. Animal data suggest bremelanotide activates presynaptic MC4Rs on mPOA neurons, which increases release of dopamine, an excitatory neurotransmitter linked to sexual desire PMID: 33455598. HSDD is thought to involve an imbalance between excitatory and inhibitory signals in the brain (dopamine, norepinephrine, serotonin, estradiol, testosterone), and melanocortins sit on the excitatory side of that system PMID: 33455598.
This is why PT-141 gets described as a "desire" or "arousal" compound rather than an erection-on-demand drug. It changes central signaling upstream of the physical response.
FDA Approval: Vyleesi and the RECONNECT Trials
The one FDA-approved PT-141 product is Vyleesi, approved in 2019 as a self-administered, on-demand subcutaneous therapy for premenopausal women with acquired, generalized HSDD PMID: 31429064. That approval rests on published trial evidence.
The pivotal data came from RECONNECT, two identical Phase 3, randomized, double-blind, placebo-controlled trials (Study 301, NCT02333071; Study 302, NCT02338960) of bremelanotide 1.75 mg subcutaneously, as-needed, in 1,267 premenopausal women randomized over 24 weeks PMID: 31599840. Women on bremelanotide had statistically significant increases in the FSFI desire-domain score (integrated +0.35, P<.001) and significant reductions in desire-related distress (integrated -0.33, P<.001) versus placebo PMID: 31599840. The 1.75 mg dose itself carried forward from an earlier Phase 2b dose-ranging study, where responder rates at 1.75 mg beat placebo across seven endpoints (P<=.03) PMID: 31277966.
Benefits held up over time. A 52-week open-label extension of RECONNECT enrolled 684 women and reported sustained improvements in desire and distress with no new safety signals PMID: 31599847.
How It Differs From PDE5 Inhibitors (Sildenafil)
The cleanest way to understand PT-141 is by contrast with viagra-class drugs. PDE5 inhibitors work peripherally: they block phosphodiesterase-5, raise cGMP, relax smooth muscle, and increase blood flow to erectile tissue. PT-141 never touches that pathway; it acts centrally on desire and arousal signaling. Because it isn't a vasodilator, bremelanotide isn't associated with the hypotension seen with PDE5 inhibitors PMID: 17584134.
| Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors (e.g., sildenafil) |
|---|---|---|
| Molecular target | Melanocortin receptors (MC4R primarily) | Phosphodiesterase-5 enzyme |
| Site of action | Central (CNS / hypothalamus) | Peripheral (vasculature, smooth muscle) |
| Primary effect studied | Sexual desire / arousal | Blood flow / erectile response |
| Blood pressure | Small transient increase; no PDE5-type hypotension | Can lower blood pressure |
| FDA-approved form | Vyleesi, 1.75 mg subcutaneous (HSDD, premenopausal women) | Oral tablets (erectile dysfunction) |
| Research note | Melanocortin agonist; central desire pathway | Vasodilator; peripheral mechanism |
The two mechanisms can act in parallel. A small crossover pilot (n=19) found that subtherapeutic intranasal PT-141 (7.5 mg) plus low-dose sildenafil (25 mg) produced a greater erectile response than sildenafil alone, and was well tolerated PMID: 15833522. That result is a direct illustration of the central-plus-peripheral distinction.
The Intranasal History in Men's ED
Before it was a subcutaneous women's-health drug, PT-141 was studied as a nasal spray for erectile dysfunction. A randomized, double-blind, placebo-controlled trial of intranasal bremelanotide 10 mg in 342 men who didn't respond to sildenafil reported positive clinical results in 33.5% on bremelanotide versus 8.5% on placebo (P=0.03), with more intercourse satisfaction but also more drug-related side effects PMID: 18206919. Reviews from that era described bremelanotide as a nasally administered peptide with erectogenic properties tied to melanocortin receptors in the CNS, studied in both men and women PMID: 17584134.
Development eventually shifted to the subcutaneous route for the approved HSDD indication. The intranasal formulation was never FDA-approved.
Known Effects From the Literature
Melanocortin activity produces a recognizable side-effect signature, and it's well documented. In the integrated Phase 3 population (n=1,247), the most common adverse events on bremelanotide versus placebo were nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%), and injection-site reactions PMID: 35147466. Most events were mild-to-moderate, and nausea was the leading reason people stopped PMID: 35147466. The 52-week extension reported nearly identical rates: nausea 40.4%, flushing 20.6%, headache 12.0% PMID: 31599847.
Two other effects come directly from the drug's mechanism. Bremelanotide causes small, transient but statistically significant blood-pressure increases after dosing PMID: 35147466. And because melanocortins drive pigmentation, focal hyperpigmentation of skin can occur: rare at label-recommended dosing, but seen in more than a third of subjects after up to 16 consecutive daily doses PMID: 35147466. There are also drug interactions worth noting, since bremelanotide can lower plasma levels of orally administered naltrexone and indomethacin PMID: 35147466.
Doses Studied and How the Research Community Talks About It
What follows separates two very different things: regulatory and study facts (stated with citations) and community anecdote (descriptive only, unvalidated).
Approved and study doses (facts). The FDA-approved Vyleesi dose is 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with a labeled maximum of one dose per 24 hours and 8 doses per month. This is the same 1.75 mg subcutaneous dose evaluated in the RECONNECT Phase 3 trials PMID: 31599840 and carried forward from the earlier Phase 2b dose-ranging study PMID: 31277966. The historical intranasal men's-ED research used lower single-digit to low-double-digit milligram intranasal doses (7.5 mg in a combination pilot, 10 mg in the salvage trial) PMID: 15833522PMID: 18206919, a route that is not approved.
| Context | Dose reported | Status |
|---|---|---|
| Vyleesi FDA label (HSDD, premenopausal women) | 1.75 mg SC, as-needed, >=45 min before activity | FDA-approved regulatory fact |
| RECONNECT Phase 3 trials | 1.75 mg SC as-needed | Published trial PMID: 31599840 |
| Phase 2b dose-ranging | 1.75 mg SC (dose carried into Phase 3) | Published trial PMID: 31277966 |
| Intranasal men's ED research | ~7.5-10 mg intranasal | Investigational, not approved PMID: 15833522PMID: 18206919 |
Community practice (descriptive, anecdotal). In peptide and biohacking forums, PT-141 is commonly framed as a libido or desire/arousal compound used by both men and women, and described as centrally acting rather than an erection-on-demand drug. Timing reports generally cluster around 45 minutes to a few hours before anticipated activity, consistent with the label's window, and some people describe dosing earlier in the day to let initial nausea settle. Nausea is by far the most-discussed side effect in community reports, which lines up with the roughly 40% first-dose trial rate; a frequently repeated observation is that it's worst on the first dose and eases afterward. Skin darkening, freckling, and mole changes come up as a melanocortin concern, and the general leaning is toward infrequent, as-needed use rather than daily dosing. Off-label subcutaneous "microdosing" at fractions of 1.75 mg also gets discussed, often framed as starting low to gauge nausea.
Sourcing and COA Verification (Research-Use-Only)
If you're referencing PT-141 as a research compound, the same rule applies as with any peptide: a per-lot certificate of analysis (COA) matters more than any label claim. Learn what a real one shows in how to read a peptide COA, and cross-check vendors against the vendor scorecard.
One COA-per-lot option BodyHackGuide features is BHG Labs, which lists a PT-141 atomized solution. Availability varies, and it is currently listed as out of stock at the time of writing, so check current stock before relying on it rather than assuming it's available. Reader code REDDIT takes 10% off. Independent vendor; BodyHackGuide may earn a commission. It's one reputable option among several, not the only one, so verify the COA regardless of where you source. You can also see the on-site reference at /compound/pt-141.
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!